Published in final edited form as:

ACS Chem Biol. 2013 March 15; 8(3): 617–625. doi:10.1021/cb300466n.

Calcium Dependent Ligand Binding and G-protein Signaling of Family B GPCR Parathyroid Hormone 1 Receptor Purified in Nanodiscs

Nivedita Mitra^{1,†}, Yuting Liu^{1,†}, Jian Liu¹, Eugene Serebryany¹, Victoria Mooney¹, Brian T. DeVree², Roger K. Sunahara², and Elsa C. Y. Yan¹

¹Department of Chemistry, Yale University, New Haven, CT 06520

²Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI 48109

Abstract

GPCRs mediate intracellular signaling upon external stimuli, making them ideal drug targets. However, little is known about their activation mechanisms due to the difficulty in purification. Here, we introduce a method to purify GPCRs in nanodiscs, which incorporates GPCRs into lipid bilayers immediately after membrane solubilization, followed by single-step purification. Using this approach, we purified a family B GPCR, parathyroid hormone 1 receptor (PTH1R), which regulates calcium and phosphate homeostasis and is a drug target for osteoporosis. We demonstrated that the purified PTH1R in nanodiscs can bind to PTH(1-34) and activate G protein. We also observed that Ca²⁺ is a weak agonist of PTH1R and Ca²⁺ in millimolar concentration can switch PTH(1-34) from an inverse agonist to an agonist. Hence, our results show that nanodiscs are a viable vehicle for GPCR purification, enabling studies of GPCRs under precise experimental conditions without interference from other cellular or membrane components.

Integral membrane proteins can be challenging to purify and study. G-protein-coupled receptors (GPCRs) are the largest class of integral membrane proteins found in the human genome and are represented by approximately 1000 genes⁷. These 7-helical-transmembrane proteins constitute a major portal for intercellular communication. Upon binding to their ligand on their extracellular or transmembrane domain, GPCRs transduce a signal via conformational changes to the cytoplasmic side, which then couples with G-proteins to start signaling cascades. Based on GPCRs' function and amino acid sequence, they are classified into 5 families (A to E), of which families A, B, and C are best studied with respect to their ligand binding, function, and G-protein coupling¹⁰. However, most biophysical and activation mechanism studies have been performed only on family A GPCRs, using model systems, such as rhodopsin and β_2 -adrenergic receptor^{1,12,14,36,37,47,55}. These studies reveal precise information about roles of amino acids and helical movements in the transmembrane region upon activation. Such detailed information is unavailable for families B and C,

Address Correspondence to: Elsa C. Y. Yan, Department of Chemistry, Yale University, New Haven, CT 06520. Phone: (203) 436-2509; Fax: (203) 432-6144; elsa.yan@yale.edu.

[†]Equal contribution.

Supporting Information

This material is available free of charge via the Internet at <http://pubs.acs.org>.

largely due to difficulty in purifying them while retaining their activity for biophysical studies. Apart from reasons such as low cellular expression levels, the difficulty in purifying GPCRs can also arise from their labile membrane-embedded hydrophobic domains, which require detergents for solubilization and extraction from the plasma membrane. Solubilization is a critical step in the purification procedure, where the target GPCR is separated from the membrane lipids of the expressing cell systems. Traditionally, once GPCRs are separated from cell membranes with a detergent, all subsequent purification steps are also done in detergent¹³. The purified GPCRs are then either stored in detergent or reconstituted into lipid environments⁴³. Such prolonged exposure to detergent could be an additional contributing factor in denaturation of GPCRs during purification.

Here, we propose that minimizing detergent contact with GPCRs can preserve their structure and stabilize them. One way to achieve minimal detergent contact is by using nanodiscs. Nanodiscs, also referred to as NABBs (Nanoscale Apolipoprotein Bound Bilayers)⁴¹ are a discoidal form of HDL (High-density Lipoproteins). They are composed of nanometer-sized lipid bilayers surrounded by two alpha helical membrane scaffold proteins (MSP)⁹. MSPs are modified versions of apolipoprotein A⁴⁶. Nanodiscs were first characterized by the Sligar group⁴⁶. Because nanodiscs mimic a membrane, they could be ideal vehicles for stabilization of transmembrane proteins. A recent study showed that MSP can be replaced by polymers to form particles called Lipodisq³¹. Because nanodiscs mimic a membrane, they could be ideal vehicles for stabilization of transmembrane proteins. In this study, we use nanodiscs formed by the MSP, MSP1E3D1 to purify GPCRs. We incorporate our target GPCRs into nanodiscs immediately after solubilization from the expression system to minimize detergent contact, and purify the receptors by single-step affinity chromatography while the receptors are in the lipid environment of nanodiscs (Fig. 1).

Although nanodiscs have been applied to study membrane proteins^{4,6,8,19,23,35,44,54}, they have not been used as a vehicle to purify GPCRs. Previous studies have shown that when membrane proteins are incorporated into nanodiscs, they display improved stability and activity^{40,41}. Nanodiscs were used to incorporate rhodopsin, β_2 -adrenergic receptor, μ -opioid receptor and CCR5 for examining their interactions with G-proteins^{19,22,41,51,52}. Moreover, rhodopsin incorporated into nanodiscs can couple with downstream signaling proteins, including rhodopsin kinase and arrestin-1^{5,50}. However, in these previous studies, GPCRs were incorporated into nanodiscs after being purified in detergent. Although nanodiscs have been applied to directly purify a membrane-anchored protein, cytochrome P450 monooxygenase²⁴, nanodiscs have never been used as a means for purifying integral membrane proteins, such as GPCRs.

Here, we use parathyroid hormone 1 receptor (PTH1R) as a model system, of which the purification in detergent has been reported, to establish our proposed nanodisc methodology for purifying GPCRs. The receptor belongs to family B GPCRs. To date, there have been a small number of successful cases of purifying family B GPCRs, which include pituitary adenylate cyclase-activating peptide receptor purified from bovine brain²⁹ and insect cells³⁰, PTH1R purified from COS-7 cells³³, HEK293S cells¹¹ and *E. coli*²⁷, glucagon-like peptide 1 receptor purified from both *E. coli*⁴² and insect cells⁴⁹, and two other receptors, corticotrophin-releasing factor receptors 1 and 2 β , obtained using cell-free expression

methods¹⁸. In this study, we choose PTH1R as our target receptor, because it has been shown to be stable in detergents. Thus, it is a good model system for establishing and standardizing the purification protocol.

PTH1R is expressed in osteoblasts in bone and tubule epithelial cells in the kidney and is a target for osteoporosis treatment²⁵. It has two endogenous ligands, parathyroid hormone 1 (PTH) and parathyroid hormone-related protein (PTHrP). It regulates calcium and phosphate homeostasis in blood and extracellular fluids upon binding to PTH, and subsequent coupling with either G_s or G_q , which activates the adenylyl cyclase or phospholipase C signaling pathways, respectively²⁵. Association of PTH1R with PTHrP is important in the development of organs, such as bone, heart, mammary glands and other tissues^{21,25,53}. A truncated version of PTH, PTH(1-34) that has the first 34 amino acids, maintains the same functions as the full-length ligand²⁵. Paradoxically, while activation of PTH1R by PTH or PTH(1-34) results in bone resorption (release of Ca^{2+} from bone), intermittent injection of PTH(1-34) can enhance bone formation and is an FDA-approved treatment for osteoporosis¹⁶.

In this study, we extracted PTH1R in nanodiscs and characterized the properties and functions of the purified PTH1R incorporated in nanodiscs (PTH1R-ND). We used fluorescence anisotropy to study the binding of fluorescently labeled PTH(1-34) to the purified PTH1R-ND and obtained binding constants at various Ca^{2+} concentrations. We also used a fluorescently labeled non-hydrolyzable GTP analogue to examine the ability of PTH1R-ND to activate G-protein (G_s) in response to the binding of PTH(1-34). Our studies reveal that both ligand binding and G-protein activity of PTH1R-ND strongly depend on Ca^{2+} concentration. In particular, Ca^{2+} at millimolar concentrations can switch PTH(1-34) from inverse agonist to agonist and Ca^{2+} alone can weakly activate PTH1R under the conditions of our experiments. These results demonstrate that nanodiscs can be a viable vehicle for GPCR purification, which enables precise control of experimental conditions, such as Ca^{2+} concentration, for functional characterization that would be difficult in cells or membrane preparations.

RESULTS

Purification of PTH1R in nanodiscs

The purification process starts with expressing a full-length PTH1R tagged with the 1D5 epitope (TETSQVAPA) in HEK293S cells (Fig. 1). Membrane fractions of the PTH1R expressing cells were isolated (described in Supplementary Methods) and then solubilized using *n*-dodecyl- β -D-maltopyranoside (DDM). The solubilized membrane fractions were incubated with 1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphocholine (POPC) and MSP1E3D1. Subsequently, Bio-Beads were added to remove DDM by physical adsorption. Upon removal of DDM, nanodiscs form spontaneously, which incorporate POPC and the membrane components of the HEK293S cells, including the over-expressed 1D5-tagged PTH1R. Then, 1D4 antibody coupled resin was added to the assembly mix to specifically bind PTH1R incorporated in nanodiscs (PTH1R-ND). The resin was washed and the bound PTH1R-ND was eluted using the 1D5 peptide. We established this protocol through several rounds of optimization of various experimental parameters, including the lipid to detergent

ratio, the MSP1E3D1 to membrane protein ratio, the MSP1E3D1 to lipid ratio, and the amount of Bio-Beads, which are detailed in the Supporting Information. Using this optimized protocol to purify PTH1R, we obtained a yield ranging roughly from 0.05 to 0.2 μ g of PTH1R per 10-cm plate of HEK293S cells (Supplementary Fig. 1).

Characterization of physical properties of PTH1R-ND

Next, we characterized the size, size distribution, and purity of PTH1R-ND. We used size exclusion chromatography to measure the Stokes diameter of PTH1R-ND. The gel filtration profile showed a major peak at 10.7 mL (Fig. 2a). Calibration with protein standards (vertical bars on the top of the elution profile), confirmed that this peak corresponded to a Stokes diameter of 12.5 nm. We would like to point out here that the Stokes diameter assumes a spherical shape of the particle being measured, whereas nanodiscs are disc shaped. The profile also contained an earlier eluting peak, representing aggregates that are too large for the column to resolve. To further characterize the size and size distribution, we used transmission electron microscopy (TEM). We took several EM images and each image displayed roughly 200 particles (Fig. 2b), of which most are homogenous with a diameter of $\sim$ 15 nm (Fig. 2b, lower panel). A few particles appeared to be 2–3 times larger than the rest, which is consistent with the gel filtration profile. We also ran a SDS-PAGE gel and stained it with Coomassie blue. The gel contained two main bands with apparent molecular weights of 28 kD and 75 kD, corresponding to MSP1E3D1 and PTH1R, respectively (Fig. 2c).

Effect of Ca^{2+} on ligand binding of PTH1R-ND

Next, we examined the ligand binding activity of PTH1R-ND using fluorescence anisotropy and observed an effect of Ca^{2+} concentration on the ligand affinity. We designed a fluorescently labeled ligand, PTH(1-34)-FAM, which is labeled with 5(6)-carboxyfluorescein (FAM) at Lys13 (Fig. 3a). The concentration of PTH(1-34)-FAM was fixed at 50 nM and titrated with freshly prepared PTH1R-ND in buffer A (20 mM Tris at pH 7.4, 150 mM NaCl, 100 μ M EDTA and 3 mM MgCl_2). In the presence of 15 mM Ca^{2+} , the anisotropy of PTH(1-34)-FAM increased with an increase in PTH1R-ND concentration (Fig. 3b). This increase is due to the binding of PTH(1-34)-FAM onto PTH1R-ND, resulting in a slower rotational diffusion. We analyzed the titration curve using a binding model (Supporting Information) to obtain the dissociation constant (K_d), which was reproducible over four experiments with an average value of 32.8 ± 5.6 nM. When no additional Ca^{2+} is added, the increase in anisotropy of PTH(1-34)-FAM with increase in PTH1R-ND concentration is much smaller. The K_d averaged from three independent measurements is 570.3 ± 70.5 nM. When empty nanodiscs (empty-ND) are used instead of PTH1R-ND, there is no change in anisotropy even in the presence of 15 mM Ca^{2+} , suggesting that binding of PTH(1-34)-FAM is specific to PTH1R. Altogether, the results suggest that the purified PTH1R-ND can bind to PTH(1-34)-FAM. The results also show that ligand binding is highly Ca^{2+} dependent and the presence of 15 mM Ca^{2+} increases the association constant of PTH(1-34)-FAM to PTH1R-ND by an order of magnitude.

Lower affinity of ligand binding under a Ca^{2+} depleting condition

We also examined the binding of PTH(1-34)-FAM to PTH1R-ND under a Ca^{2+} depleting condition, i.e., in the presence of 200 μM EGTA. EGTA is used to remove residual Ca^{2+} in the buffer that was introduced as impurity from the buffer components (Tris-HCl, NaCl and MgCl_2). Ca^{2+} impurities on bottle labels were specified as 10 mg/kg for Tris-HCl, 0.002% for NaCl, and 0.01% for MgCl_2 . The residual Ca^{2+} in the buffer is expected to be less than 6 μM . Indeed, the concentration of Ca^{2+} in our buffer was measured using the inductively coupled plasma optical emission spectrometry (ICP-OES) method by Robertson Microlit Laboratories and found to be undetectable with a specified detection limit of 1 ppm (~ 25 μM). Thus, addition of 200 μM EGTA is expected to remove all residual Ca^{2+} . Under this condition, a titration of PTH(1-34)-FAM (50 nM) with PTH1R-ND still leads to an increase in PTH(1-34)-FAM anisotropy (Fig. 3b). However, the increase is relatively small compared to other conditions shown in Fig. 3. The K_d is measured to be 802.8 ± 82.4 nM, which is averaged from two independent measurements. Thus, depletion of Ca^{2+} weakens the binding of PTH(1-34)-FAM to PTH1R-ND. Nonetheless, this weakening effect is reversible. Addition of 15 mM of Ca^{2+} after Ca^{2+} -depletion can restore the binding affinity (Supplementary Fig. 5).

Activation of G-protein by PTH1R-ND upon binding to PTH(1-34)

In addition to ligand binding, we also examined G-protein activation. We studied activation of G_s by PTH1R-ND upon binding to unlabeled PTH(1-34) using a non-hydrolyzable fluorescently labeled GTP analogue, BODIPY FL GTP γ S (Fig. 4a). The fluorescence of BODIPY FL GTP γ S is quenched when it is in aqueous solution, but fluorescence is restored when it binds to G_s . Hence, an increase in fluorescence intensity indicates activation of G_s . Fig. 4b shows the time dependence of fluorescence intensity measured simultaneously in identical cuvettes in four sample slots of the fluorimeter. At $t = 0$, a reaction mixture, containing PTH1R-ND (20 nM), G_s (100 nM) and BODIPY FL GTP γ S (100 nM) in buffer A, is aliquoted in each of the four slots. At $t \sim 6$ min, one of the following four solutions are added into each sample slot: (1) PTH(1-34) with addition of 15 mM Ca^{2+} , (2) PTH(1-34) with addition of 5 mM Ca^{2+} , (3) PTH(1-34) without addition of Ca^{2+} , and (4) the buffer. Then, the fluorescence intensity was monitored for ~ 3 hours. The concentration of PTH(1-34) was fixed at 2 μM in all G-protein activity assays, which is expected to saturate the binding based on the measured K_d . Fig. 4b shows the fluorescent signal continues to increase in the case of buffer alone, which represents the basal activity. Upon addition of PTH(1-34) in the presence of 5 or 15 mM Ca^{2+} , the fluorescence intensity further increases relative to the basal level. Such increase is larger for 15 mM than for 5 mM. Surprisingly, adding PTH(1-34) without a supplement of Ca^{2+} causes a decrease of fluorescence signal relative to the basal level. Fig. 4c shows the basal level subtracted fluorescence signal. When the buffer is supplemented with 5 and 15 mM of Ca^{2+} , addition of PTH(1-34) induces a positive response, indicating that PTH(1-34) is an agonist. In contrast, when the buffer is not supplemented with Ca^{2+} , addition of PTH(1-34) leads to a negative response, indicating that PTH(1-34) is an inverse agonist. These observations were made in five different experiments using independently prepared PTH1R-NDs.

Control experiments

To confirm that the G-protein activity and Ca^{2+} effect shown in Fig. 4 are specific to PTH1R, we performed control experiments where we replaced PTH1R-ND with empty-ND and examined the G-protein activity in response to addition of Ca^{2+} and empty-NDs. At $t = 0$, a mixture of G_s (100 nM) and BODIPY FL GTP γ S (100 nM) is aliquoted into two sample slots and the fluorescence intensities are monitored simultaneously (Fig. 5). In the first 45 min, the fluorescence signals remain unchanged, suggesting that G_s exhibits no basal activity by itself. At $t \sim 45$ min, 15 mM Ca^{2+} is added to slot 1 while Buffer A is added to slot 2. The fluorescence signals of the two samples stay the same for another 45 min, suggesting that BODIPY-GTP γ S does not bind to G_s and that Ca^{2+} cannot activate G_s in the absence of PTH1R-ND. At $t \sim 90$ min, empty-ND is added to slot 1 while Buffer A is added to slot 2. The fluorescence intensity is monitored for additional 70 min. Aside from the initial drop in signal due to dilution, the fluorescence intensity does not change, indicating that empty-NDs cannot activate G_s . We repeated these control experiments twice and made the same observations. We conclude that the observed G_s activity (Fig. 4) is specific to PTH1R and that the effect of Ca^{2+} on the G-protein activity (Fig. 4) is exerted through the purified PTH1R-ND.

Residual Ca^{2+} required for basal PTH1R activity

To test whether residual Ca^{2+} in buffer is important for G-protein activity, we performed the same G-protein activity assay under a Ca^{2+} -depleting condition (200 μM EGTA) (Fig. 6a). At $t = 0$, the three sample slots in the fluorimeter are filled with the same mixture of PTH1R-ND, G_s , and BODIPY FL GTP γ S. At $t \sim 15$ min, one of the following solutions are added to each sample: (1) 2 μM PTH(1-34), (2) 2 μM PTH(1-34) with 200 μM EGTA and (3) 2 μM PTH(1-34) with 5 mM Ca^{2+} (specified as final concentrations). Addition of PTH(1-34) in the presence of EGTA gives a small fluorescence response, suggesting that PTH(1-34) can barely activate G-protein via PTH1R-ND under the Ca^{2+} depleting condition. In contrast, addition of PTH(1-34) in the absence of EGTA results in an increase in fluorescence signal. The presence of 15 mM Ca^{2+} produces a more robust increase in signal than when no Ca^{2+} is added. Moreover, we tested the effect of depletion of Ca^{2+} on the basal activity, i.e., in the absence of the ligand. Fig. 6b shows that after two solutions, (1) Buffer A and (2) Buffer A with 200 μM EGTA, are added, the increase in fluorescent signal is greater in the absence of EGTA than in the presence of EGTA. The results suggest that residual Ca^{2+} in the buffer is important for the basal activity of PTH1R-ND.

Ca^{2+} alone as a weak agonist of PTH1R

We further compared the effect of PTH(1-34) and Ca^{2+} on activating G-protein via PTH1R-ND (Fig. 6c). To the same mixture of PTH1R-ND, G_s , and BODIPY FL GTP γ S, in three sample slots of the fluorimeter, we added one of the following three solutions: (1) 2 μM PTH(1-34) with 5 mM Ca^{2+} , (2) 5 mM Ca^{2+} , and (3) Buffer A—all mentioned as final concentrations. Addition of 5 mM Ca^{2+} in the absence of PTH(1-34) leads to a greater increase in fluorescence relative to buffer alone, suggesting that Ca^{2+} alone can activate G-protein in the presence of PTH1R-ND. However, this increase is much less than when both Ca^{2+} and PTH(1-34) are present. This result reveals that Ca^{2+} by itself can act as an agonist

under our experimental conditions, but the effect is relatively weak when compared with PTH(1-34) in the presence of Ca^{2+} .

DISCUSSION

We have established a nanodisc-based protocol to purify a family B GPCR, PTH1R. This protocol incorporates PTH1R into nanodiscs immediately after membrane solubilization to avoid prolonged contact with detergents. Once in nanodiscs, PTH1R is isolated by single-step affinity purification (Fig. 1). Also, we have developed functional assays to detect ligand binding and G-protein activation. Ligand binding was detected with a fluorescently labeled ligand using fluorescence anisotropy and G-protein activity was examined using a non-hydrolyzable fluorescently labeled GTP analogue. Using these assays, we confirmed signal transduction activity of the purified PTH1R-ND. We also showed that Ca^{2+} has a profound effect on the signal transduction activity of purified PTH1R-ND under our experimental conditions. Addition of 15 mM Ca^{2+} enhanced the binding of PTH(1-34) to PTH1R-ND by a factor of 17 ± 4 , in comparison to when experiment was done in the presence of residual Ca^{2+} , i.e., without addition of EGTA, and by a factor of 24 ± 5 in comparison to when experiment was done in the absence of any Ca^{2+} , i.e., in the presence of 200 μM EGTA. Moreover, Ca^{2+} by itself was able to act as a weak agonist for PTH1R-ND to activate G_s . Unexpectedly, PTH(1-34) behaved as an inverse agonist when no additional Ca^{2+} was present but supplementing with millimolar amounts (5 or 15 mM) of Ca^{2+} switched PTH(1-34) to an agonist under our experimental conditions.

Our observations of the effect of Ca^{2+} on the signaling process of PTH1R in nanodiscs generate a number of important questions: What is the molecular mechanism of the Ca^{2+} effect? How does Ca^{2+} change the structure and dynamics of PTH1R in both micromolar and millimolar concentration? How do these changes in PTH1R alter ligand binding and G-protein activation? What is the physiological relevance of the Ca^{2+} on PTH1R signaling in modulating Ca^{2+} homeostasis? While PTH(1-34) is known to trigger bone resorption (release of Ca^{2+} from bone), intermittent injection of PTH(1-34) is a treatment for osteoporosis. Could the observed effect of Ca^{2+} on the PTH1R signaling process provide molecular insights into the pharmacological efficacy of the PTH(1-34) treatment? As for now, all these questions remain unanswered. However, we have started exploring some of them.

We hypothesized that Ca^{2+} can alter the secondary structure of PTH(1-34) in solution to enhance its binding to PTH1R-ND. Previous studies have shown that many peptide ligands of family B GPCRs adopt α -helical structures upon binding to the receptors but exhibit little or no secondary structure in solution^{20,32}. PTH(1-34) is found to be partially helical in solution²⁶, but is crystallized as a full helix¹⁷. To test whether Ca^{2+} could increase the α -helical content in PTH(1-34) in solution and thereby enhance the binding, we acquired circular dichroism spectra of PTH(1-34) at 0–15 mM of Ca^{2+} . The spectra revealed the presence of both α -helical and disordered structures (Supplementary Fig. 6). No change in secondary structure was observed upon addition of Ca^{2+} . Hence, Ca^{2+} does not promote formation of α -helical structure in PTH(1-34) to enhance binding.

Our results show that Ca^{2+} at a concentration of 15 mM can alter the affinity of PTH(1-34) towards PTH1R-ND and the G-protein activity of PTH1R-ND. Nonetheless, the Ca^{2+} concentration in blood is strictly regulated at ~2.5 mM, of which only half exists as free ions⁴⁸. However, local Ca^{2+} concentrations in the extracellular fluid around osteoblasts, bone cells that express PTH1R, can be momentarily boosted up to ~40 mM during the bone resorption process⁴⁵. It would be interesting to test whether this instantaneous increase of Ca^{2+} concentration to millimolar levels at the osteoblasts *in vivo* could further mediate bone resorption via PTH1R signaling.

Moreover, the effects of Ca^{2+} on the signaling activity of PTH1R-ND imply that there could be Ca^{2+} binding site(s) on the receptor and/or that Ca^{2+} can alter protein dynamics and shift PTH1R to a more active-like conformation. When residual Ca^{2+} is removed from the buffer by EGTA, PTH1R-ND can barely activate G-protein both in the presence and absence of ligand. The effect of millimolar levels of Ca^{2+} on both ligand binding and G_s activity also points towards interactions of Ca^{2+} with PTH1R and/or the signaling complex, PTH(1-34)-PTH1R-ND- G_s . We are in the process of building homology models in conjunction with mutagenesis to explore the possibility of identifying the Ca^{2+} -binding site(s).

An important factor that might contribute towards the behavior of any membrane protein is the composition of lipids in the bilayer in its immediate vicinity. A recent study on the family A GPCR, neurotensin receptor 1 (NTR1) in nanodiscs has demonstrated that although this receptor binds to its ligand independent of lipid composition in the lipid bilayer, its interaction with the G-protein, G_q , is determined by whether the nanodisc is composed exclusively of zwitterionic POPC or a mixture of POPC and the negatively charged POPG (1-palmitoyl-2-oleoyl-*sn*-glycero-3-phospho-(1'-*rac*-glycerol))¹⁵. Increasing the proportion of the negatively charged POPG resulted in increased affinity for G_q , as well as increased nucleotide exchange rates. Similarly, by increasing the ratio of negatively charged POPS (1-palmitoyl-2-oleoyl-*sn*-glycero-3-phospho-L-serine) to POPC, rhodopsin incorporated in nanodiscs showed increased association with arrestin-1⁵.

In this manuscript, we have used POPC alone to make nanodiscs. Taking into account the lipid contribution from the cell membrane, we will have only ~7% non-POPC lipids in the nanodiscs (See Supplementary Results for estimation). It is quite likely that upon changing the lipid content of the PTH1R-ND bilayer to where we have significant amounts of negatively charged lipids, such as POPG or POPS, we will observe an increased association of PTH1R-ND with the G_s trimer. We plan to perform further experiments by varying the lipid content of the nanodisc bilayer to observe any changes in the association of G-protein with PTH1R.

The existence of GPCR oligomers and consequences of these oligomers on GPCR function, have been under intense study for some time. The ability to control the number of receptor/ GPCR molecules in the nanodisc makes them an important tool for the study of the effect of receptor oligomerization on ligand binding and signal transduction. Using nanodiscs, it has been shown that GPCRs such as rhodopsin^{3,5,50}, β_2 -adrenergic receptor⁵¹, neurotensin¹⁵ and μ -opioid receptor²² monomers are sufficient for functional association with G-protein. In

fact, monomeric rhodopsin in nanodiscs is also shown to undergo phosphorylation by rhodopsin kinase (GRK1) and bind with arrestin-1⁵.

FRET (Fluorescence resonance energy transfer) and BRET (bioluminescence resonance energy transfer) studies in live cells have shown that in the absence of bound ligand, PTH1R can exist as a dimer in the cell membrane³⁴. But this does not necessarily imply that PTH1R solubilized from cell membranes using detergents will continue to exist as a dimer in the resulting micelles. For instance, β_2 -adrenergic receptor has been shown to dimerize in the cell membrane² but is found to be a monomer in detergent micelles after solubilization⁵¹, i.e. the dimer does not survive the high concentration of detergent. Thus, it is likely that PTH1R also forms monomers in detergent micelles and exists in the monomeric state in the nanodisc as well. In the future, we plan to carry out experiments to determine the oligomerization status of PTH1R in nanodiscs and understand the function of the receptor with respect to its oligomerization status.

In conclusion, we have established a method to purify the family B GPCR, PTH1R, in nanodiscs and developed functional assays to examine ligand binding and G-protein activity of the protein. The ligand binding assays can be adapted to other family B GPCRs, while the G-protein activity assay can be generally applied to other GPCRs. Our nanodisc based method enables biochemical and functional characterization of the receptor in the absence of interfering factors from the cell or membrane preparations, including various interacting proteins and feedback regulations, facilitating our observation of the profound effects of Ca^{2+} on the signaling process of PTH1R. The observations lead to a number of questions that introduce opportunities for further research on PTH1R's function. The purification method yields the receptor directly into nanodiscs, which could be an ideal platform for biophysical characterization, such as single-molecule spectroscopy and electron paramagnetic resonance spectroscopy. Such studies can potentially reveal a detailed activation mechanism in terms of conformational changes in the transmembrane region, which has remained almost unknown for family B GPCRs. The purification method utilizing nanodiscs can be readily tested and optimized for all other GPCRs with minimum adaptations, and can theoretically be extended to other integral membrane proteins, potentially yielding a general method for purifying transmembrane proteins that cannot be purified in detergent systems.

METHODS

Materials

Three peptides were synthesized at the Keck Biotechnology Resource Laboratory at Yale University: 1D5 peptide (TETSQVAPA), PTH(1-34), and PTH(1-34)FAM, i.e., PTH(1-34) conjugated to 5(6)-carboxyfluorescein at Lys 13 (Fig. 3a). BODIPY FL GTP γ S (Fig. 4a) was purchased from Invitrogen. Membrane scaffold protein (MSP1E3D1), was expressed and purified as described previously⁴⁶ with minor modifications (see Supplementary Methods). The lipid, 1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphocholine (POPC), was obtained from Avanti Polar Lipids and the detergent, *n*-dodecyl- β -D-maltopyranoside (DDM), from Anatrace. All other chemicals were analytical grade obtained from Sigma or American Biochemicals.

Expression of Human PTH1R in HEK293 Cells

The human PTH1R was expressed with a 1D5 tag (TETSQVAPA) at its C-terminal, in the tetracycline inducible vector pACMV-tetO in HEK293S *GnTI*- cells^{38,39}. Details of the plasmid construction and cell line generation are described in Supplementary Methods. PTH1R stable cells were induced with 0.55 mg/mL sodium butyrate and 2 µg/mL tetracycline and maintained under 5% CO₂/95% air atmosphere in 1:1 DMEM:F12 supplemented with 10% FBS. After 48 hrs, membrane fractions were isolated as described in Supplementary Methods.

Nanodisc Assembly

Preparations of solubilized POPC, MSP1E3D1, and membrane fraction pellet of the HEK293 cells are described in detail in Supplementary Methods. The pellet from about forty five to sixty 10-cm plates was resuspended in 600 µL of Solubilization Buffer (50 mM Tris pH 7.4, 150 mM NaCl, 5 mM CaCl₂, 5 mM MgCl₂, 2 mM EDTA, 10% glycerol and 0.5% DDM) in the presence of Protease Inhibitor Cocktail Set III (EMD Biosciences) for 1 hr at 4°C, and then spun at 15,000 × g for 15 min. The supernatant was quantified for total protein using the Pierce BCA protein assay kit (Thermo Scientific). Using an average MW of 40,000 for membrane proteins²⁸, the protein concentration was calculated. The nanodiscs were assembled in multiple 1.5 mL centrifuge tubes in a final volume of 400 µL of assembly mixture per tube. The concentration of the different components were: 90 µM of MSP1E3D1, 8 mM of POPC and 180 µg (~11 µM) of total membrane protein made up to a final volume in a buffer containing 50 mM Tris pH 7.4, 150 mM NaCl, 5 mM MgCl₂, 5 mM CaCl₂, 4 mM EDTA, 4% glycerol. The nanodisc assembly mix was incubated on ice for 45 minutes and then transferred into another 1.5 mL centrifuge tube containing 150 mg of washed Bio-Beads SM-2 (Bio-Rad) to initiate nanodisc formation. The mixture was gently mixed overnight at 4°C. Next morning, the assembled nanodiscs were affinity purified as detailed in Supplementary Methods.

Expression and Purification of G_s Heterotrimer

G_s heterotrimer was expressed and purified exactly as described previously³⁶. Briefly, bovine G_{αs} short, His6-rat G_{β1} and bovine G_{γ2} were expressed together as the heterotrimer in HighFive insect cells and solubilized with sodium cholate. The protein was exchanged into DDM detergent and purified by using Ni-NTA, Mono-Q, and Superdex 200 chromatography.

Size Exclusion Chromatography

Purified PTH1R-containing nanodiscs were resolved using a Superdex^{TM} 200 10/300 GL column at a flow rate of 0.4 mL/min. Five protein standards were used to calibrate the column: thyroglobulin (17.2 nm), apoferritin (12.2 nm), alcohol dehydrogenase (9.1 nm), bovine serum albumin (7.2 nm) and carbonic anhydrase (4 nm).

Electron Microscopy

A 4 µL of sample at 80 nM was applied to a glow-discharged carbon-coated EM grid and negatively stained with 2% uranyl acetate (w/v) solution. The specimen was subsequently

examined in a FEI Tecnai-12 electron microscope operated at 120 kV. Images were collected as 4096×4096-pixel 8-bit gray-scale Gatan Digital Micrograph 3 (DM3) files on a Gatan Ultrascan 4000 CCD camera at 52,000×. Particle sizes were estimated using Eman2.

Ligand Binding Assays

The binding between PTH and PTH1R-ND was determined by fluorescence anisotropy using PTH(1-34)-FAM. We confirmed that this FAM-labeled peptide was able to bind PTH1R on PTH1R-expressing cells using flow cytometry (see Supporting Information). In our binding assay shown in Figure 2, a 50 nM solution of PTH(1-34)-FAM was incubated with different concentrations of nanodiscs in a buffer containing 20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 100 μ M EDTA, 3 mM MgCl₂ and with CaCl₂ concentration as indicated. Titration using empty nanodiscs under the same conditions was set up as a control experiment. The measurements were made on a PTI QuantaMaster C-61 two-channel fluorescence spectrophotometer with excitation (497 nm) and emission (518 nm) slit widths of 5 nm. The ligand was mixed with PTH1R nanodiscs in a cuvette; the entire sample in the cuvette was pipetted up and down 3–4 times for thorough mixing and then incubated for one minute. The anisotropy was averaged over 60 seconds with one reading per second. All experiments were performed at 30°C. Anisotropy was measured before and after adding CaCl₂ to the cuvette, with a one-minute wait after adding calcium. Anisotropy data were fitted using **Equation (1)** with three fitting parameters K_d , r_b and r_f (see Supporting Information). The value of r_b obtained from the data fitted in the presence of calcium was used for fitting in the calcium free condition.

G-Protein Activation Assay

We measured G_s activation using BODIPY FL GTP γ S, whose fluorescence intensity increases upon binding to the G-protein. The G-protein association with BODIPY-GTP γ S was monitored using a fluorescence spectrophotometer (Cary Eclipse, Varian Inc.) with a multi-cell peltier block, with 2.5 nm excitation (500 nm) and 5 nm emission (511 nm) slit widths at 30°C. Reaction buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 100 μ M EDTA, 3 mM MgCl₂), 100 nM G_s, 100 nM BODIPY-GTP γ S, and 20 nM PTH1R nanodisc were added in a cuvette to a final volume of 54 μ L. Fluorescence was monitored for about six minutes before addition of 6 μ L of either PTH(1-34) alone to a final concentration of 2 μ M or PTH(1-34) with CaCl₂ at 5 or 15 mM final concentration. Stock solutions of all reagents in the reaction were made in reaction buffer except for G_s, which was diluted in 0.2% DDM used to stabilize the G- protein. The final reaction mixture, containing 78 μ M DDM, was found to have no effect on the stability of nanodiscs within the timescale of the G-protein activity assay (see Supporting Information).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors would like to thank J. Wysolmerski, C. Crews, V. Batista, I. Rivalta, Y. Guo, and L. Fu (Yale University) for useful discussions and X. Li for assistance in the experiments. We thank H. Wang (Yale

University), currently at Tsinghua University (China, PR), for the help with electron microscopy imaging. We thank P. Reeves (University of Essex) for providing the pACMV-*terO* vector and HEK293S *GnTI*- cells. N.M. acknowledges the support from the Seessel Postdoctoral Fellowship and J.L. acknowledges the support from the Anderson Postdoctoral Fellowship. V.M. is the recipient of the National Science Foundation fellowship (DGE-0644492) and E.S. was the recipient of the Yale-HHMI Future Scientist Fellowship and the Sackler Undergraduate Fellowship. E.Y. is the recipient of the NSF CAREER Award. This work was supported by the Yale Setup Fund.

References

1. Altenbach C, Kusnetzow AK, Ernst OP, Hofmann KP, Hubbell WL. High-resolution distance mapping in rhodopsin reveals the pattern of helix movement due to activation. *Proc Natl Acad Sci USA*. 2008; 105:7439–7444. [PubMed: 18490656]
2. Angers S, Salahpour A, Joly E, Hilairiet S, Chelsky D, Dennis M, Bouvier M. Detection of beta(2)-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET). *Proc Natl Acad Sci USA*. 2000; 97:3684–3689. [PubMed: 10725388]
3. Bayburt TH, Leitz AJ, Xie GF, Oprian DD, Sligar SG. Transducin activation by nanoscale lipid bilayers containing one and two rhodopsins. *J Biol Chem*. 2007; 282:14875–14881. [PubMed: 17395586]
4. Bayburt TH, Sligar SG. Self-assembly of single integral membrane proteins into soluble nanoscale phospholipid bilayers. *Protein Sci*. 2003; 12:2476–2481. [PubMed: 14573860]
5. Bayburt TH, Vishnivetskiy SA, McLean MA, Morizumi T, Huang CC, Tesmer JJ, Ernst OP, Sligar SG, Gurevich VV. Monomeric rhodopsin is sufficient for normal rhodopsin kinase (GRK1) phosphorylation and arrestin-1 binding. *J Biol Chem*. 2011; 286:1420–1428. [PubMed: 20966068]
6. Boldog T, Grimme S, Li M, Sligar SG, Hazelbauer GL. Nanodiscs separate chemoreceptor oligomeric states and reveal their signaling properties. *Proc Natl Acad Sci USA*. 2006; 103:11509–11514. [PubMed: 16864771]
7. Conner AC, Hay DL, Simms J, Howitt SG, Schindler M, Smith DM, Wheatley M, Poyner DR. A key role for transmembrane prolines in calcitonin receptor-like receptor agonist binding and signalling: implications for family B G-protein-coupled receptors. *Mol Pharmacol*. 2005; 67:20–31. [PubMed: 15615699]
8. Denisov IG, Baas BJ, Grinkova YV, Sligar SG. Cooperativity in cytochrome P450 3A4: linkages in substrate binding, spin state, uncoupling, and product formation. *J Biol Chem*. 2007; 282:7066–7076. [PubMed: 17213193]
9. Denisov IG, Grinkova YV, Lazarides AA, Sligar SG. Directed self-assembly of monodisperse phospholipid bilayer Nanodiscs with controlled size. *J Am Chem Soc*. 2004; 126:3477–3487. [PubMed: 15025475]
10. Fredriksson R, Lagerstrom MC, Lundin LG, Schioth HB. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. *Mol Pharmacol*. 2003; 63:1256–1272. [PubMed: 12761335]
11. Gan L, Alexander JM, Wittelsberger A, Thomas B, Rosenblatt M. Large-scale purification and characterization of human parathyroid hormone-1 receptor stably expressed in HEK293S *GnTI*-cells. *Protein Expr Purif*. 2006; 47:296–302. [PubMed: 16376105]
12. Ghanouni P, Steenhuis JJ, Farrens DL, Kobilka BK. Agonist-induced conformational changes in the G-protein-coupling domain of the beta 2 adrenergic receptor. *Proc Natl Acad Sci USA*. 2001; 98:5997–6002. [PubMed: 11353823]
13. Grisshammer R. Purification of recombinant G-protein-coupled receptors. *Methods Enzymol*. 2009; 463:631–645. [PubMed: 19892196]
14. Hofmann KP, Scheerer P, Hildebrand PW, Choe HW, Park JH, Heck M, Ernst OP. A G protein-coupled receptor at work: the rhodopsin model. *Trends Biochem Sci*. 2009; 34:540–552. [PubMed: 19836958]
15. Inagaki S, Ghirlando R, White JF, Gvozdenovic-Jeremic J, Northup JK, Grisshammer R. Modulation of the interaction between neurotensin receptor NTS1 and Gq protein by lipid. *J Mol Biol*. 2012; 417:95–111. [PubMed: 22306739]

16. Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. *Bone*. 2007; 40:1434–1446. [PubMed: 17517365]
17. Jin L, Briggs SL, Chandrasekhar S, Chirgadze NY, Clawson DK, Schevitz RW, Smiley DL, Tashjian AH, Zhang F. Crystal structure of human parathyroid hormone 1–34 at 0.9-Å resolution. *J Biol Chem*. 2000; 275:27238–27244. [PubMed: 10837469]
18. Klammt C, Perrin MH, Maslennikov I, Renault L, Krupa M, Kwiatkowski W, Stahlberg H, Vale W, Choe S. Polymer-based cell-free expression of ligand-binding family B G-protein coupled receptors without detergents. *Protein Sci*. 2011; 20:1030–1041. [PubMed: 21465615]
19. Knepp AM, Grunbeck A, Banerjee S, Sakmar TP, Huber T. Direct measurement of thermal stability of expressed CCR5 and stabilization by small molecule ligands. *Biochemistry*. 2011; 50:502–511. [PubMed: 21155586]
20. Knudsen SM, Tams JW, Fahrenkrug J. Functional roles of conserved transmembrane prolines in the human VPAC(1) receptor. *FEBS Lett*. 2001; 503:126–130. [PubMed: 11513868]
21. Kronenberg HM. PTHrP and skeletal development. *Ann N Y Acad Sci*. 2006; 1068:1–13. [PubMed: 16831900]
22. Kuszak AJ, Pitchaiya S, Anand JP, Mosberg HI, Walter NG, Sunahara RK. Purification and functional reconstitution of monomeric mu-opioid receptors: allosteric modulation of agonist binding by Gi2. *J Biol Chem*. 2009; 284:26732–26741. [PubMed: 19542234]
23. Li MS, Hazelbauer GL. Core unit of chemotaxis signaling complexes. *P Natl Acad Sci USA*. 2011; 108:9390–9395.
24. Mamillapalli R, Wysolmerski J. The calcium-sensing receptor couples to Galpha(s) and regulates PTHrP and ACTH secretion in pituitary cells. *J Endocrinol*. 2010; 204:287–297. [PubMed: 20032198]
25. Mannstadt M, Juppner H, Gardella TJ. Receptors for PTH and PTHrP: their biological importance and functional properties. *Am J Physiol-Renal*. 1999; 277:F665–F675.
26. Marx UC, Adermann K, Bayer P, Forssmann WG, Rosch P. Solution structures of human parathyroid hormone fragments hPTH(1-34) and hPTH(1-39) and bovine parathyroid hormone fragment bPTH(1-37). *Biochem Bioph Res Co*. 2000; 267:213–220.
27. Michalke K, Huyghe C, Lichiere J, Graviere ME, Siponen M, Sciara G, Lepaul I, Wagner R, Magg C, Rudolph R, Cambillau C, Desmyter A. Mammalian G protein-coupled receptor expression in *Escherichia coli*: II. refolding and biophysical characterization of mouse cannabinoid receptor 1 and human parathyroid hormone receptor 1. *Anal Biochem*. 2010; 401:74–80. [PubMed: 20175983]
28. Muller DJ, Wu N, Palczewski K. Vertebrate membrane proteins: structure, function, and insights from biophysical approaches. *Pharmacol Rev*. 2008; 60:43–78. [PubMed: 18321962]
29. Ohtaki T, Masuda Y, Ishibashi Y, Kitada C, Arimura A, Fujino M. Purification and characterization of the receptor for pituitary adenylate cyclase-activating polypeptide. *J Biol Chem*. 1993; 268:26650–26657. [PubMed: 8253796]
30. Ohtaki T, Ogi K, Masuda Y, Mitsuoka K, Fujiyoshi Y, Kitada C, Sawada H, Onda H, Fujino M. Expression, purification, and reconstitution of receptor for pituitary adenylate cyclase-activating polypeptide - large-scale purification of a functionally active G protein-coupled receptor produced in Sf9 insect cells. *J Biol Chem*. 1998; 273:15464–15473. [PubMed: 9624132]
31. Orwick MC, Judge PJ, Procek J, Lindholm L, Graziadei A, Engel A, Grobner G, Watts A. Detergent-free formation and physicochemical characterization of nanosized lipid-polymer complexes: Lipodisq. *Angew Chem Int Ed Engl*. 2012; 51:4653–4657. [PubMed: 22473824]
32. Parthier C, Reedtz-Runge S, Rudolph R, Stubbs MT. Passing the baton in class B GPCRs: peptide hormone activation via helix induction? *Trends Biochem Sci*. 2009; 34:303–310. [PubMed: 19446460]
33. Pierce MM, Raman CS, Nall BT. Isothermal titration calorimetry of protein-protein interactions. *Methods*. 1999; 19:213–221. [PubMed: 10527727]
34. Pioszak AA, Harikumar KG, Parker NR, Miller LJ, Xu HE. Dimeric arrangement of the Parathyroid hormone receptor and a structural mechanism for ligand-induced dissociation. *J Biol Chem*. 2010; 285:12435–12444. [PubMed: 20172855]

35. Ranaghan MJ, Schwall CT, Alder NN, Birge RR. Green proteorhodopsin reconstituted into nanoscale phospholipid bilayers (nanodiscs) as photoactive monomers. *J Am Chem Soc.* 2011; 133:18318–18327. [PubMed: 21951206]
36. Rasmussen SG, Devree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS, Thian FS, Chae PS, Pardon E, Calinski D, Mathiesen JM, Shah ST, Lyons JA, Caffrey M, Gellman SH, Steyaert J, Skinotitis G, Weis WI, Sunahara RK, Kobilka BK. Crystal structure of the beta(2) adrenergic receptor-Gs protein complex. *Nature.* 2011; 477:549–555. [PubMed: 21772288]
37. Rasmussen SGF, Choi HJ, Fung JJ, Pardon E, Casarosa P, Chae PS, DeVree BT, Rosenbaum DM, Thian FS, Kobilka TS, Schnapp A, Konetzki I, Sunahara RK, Gellman SH, Pautsch A, Steyaert J, Weis WI, Kobilka BK. Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor. *Nature.* 2011; 469:175–180. [PubMed: 21228869]
38. Reeves PJ, Callewaert N, Contreras R, Khorana HG. Structure and function in rhodopsin: high-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-inducible N-acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line. *Proc Natl Acad Sci USA.* 2002; 99:13419–13424. [PubMed: 12370423]
39. Reeves PJ, Kim JM, Khorana HG. Structure and function in rhodopsin: a tetracycline-inducible system in stable mammalian cell lines for high-level expression of opsin mutants. *Proc Natl Acad Sci USA.* 2002; 99:13413–13418. [PubMed: 12370422]
40. Ritchie TK, Grinkova YV, Bayburt TH, Denisov IG, Zolnerchiks JK, Atkins WM, Sligar SG. Chapter 11 - Reconstitution of membrane proteins in phospholipid bilayer nanodiscs. *Methods Enzymol.* 2009; 464:211–231. [PubMed: 19903557]
41. Sakmar TP, Banerjee S, Huber T. Rapid incorporation of functional rhodopsin into nanoscale apolipoprotein bound bilayer (NABB) particles. *J Mol Biol.* 2008; 377:1067–1081. [PubMed: 18313692]
42. Schroder-Tittmann K, Bosse-Doenecke E, Reedtz-Runge S, Ihling C, Sinz A, Tittmann K, Rudolph R. Recombinant expression, in vitro refolding, and biophysical characterization of the human glucagon-like peptide-1 receptor. *Biochemistry.* 2010; 49:7956–7965. [PubMed: 20690636]
43. Serebryany E, Zhu GA, Yan EY. Artificial membrane-like environments for in vitro studies of purified G-protein coupled receptors. *Bba-Biomembranes.* 2012; 1818:225–233. [PubMed: 21851807]
44. Shi L, Shen QT, Kiel A, Wang J, Wang HW, Melia TJ, Rothman JE, Pincet F. SNARE proteins: one to fuse and three to keep the nascent fusion pore open. *Science.* 2012; 335:1355–1359. [PubMed: 22422984]
45. Silver IA, Murrills RJ, Etherington DJ. Microelectrode studies on the acid microenvironment beneath adherent macrophages and osteoclasts. *Exp Cell Res.* 1988; 175:266–276. [PubMed: 3360056]
46. Sligar SG, Bayburt TH, Grinkova YV. Self-assembly of discoidal phospholipid bilayer nanoparticles with membrane scaffold proteins. *Nano Lett.* 2002; 2:853–856.
47. Standfuss J, Edwards PC, D'Antona A, Fransen M, Xie G, Oprian DD, Schertler GF. The structural basis of agonist-induced activation in constitutively active rhodopsin. *Nature.* 2011; 471:656–660. [PubMed: 21389983]
48. Talmage DW, Talmage RV. Calcium homeostasis: how bone solubility relates to all aspects of bone physiology. *J Musculoskelet Neuronal Interact.* 2007; 7:108–112. [PubMed: 17627079]
49. Tsang C, Grihalde N, Korepanova A, Lake M, Pereda-Lopez A, Reilly RM, Walter K, Chiu M. BIOT 138-Expression and purification of the glucagon-like peptide-1 receptor. *Abstr Pap Am Chem S.* 2006; 232
50. Tsukamoto H, Sinha A, DeWitt M, Farrens DL. Monomeric rhodopsin is the minimal functional unit required for arrestin binding. *J Mol Biol.* 2010; 399:501–511. [PubMed: 20417217]
51. Whorton MR, Bokoch MP, Rasmussen SG, Huang B, Zare RN, Kobilka B, Sunahara RK. A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein. *Proc Natl Acad Sci USA.* 2007; 104:7682–7687. [PubMed: 17452637]
52. Whorton MR, Jastrzebska B, Park PS, Fotiadis D, Engel A, Palczewski K, Sunahara RK. Efficient coupling of transducin to monomeric rhodopsin in a phospholipid bilayer. *J Biol Chem.* 2008; 283:4387–4394. [PubMed: 18033822]

53. Wysolmerski JJ, Philbrick WM, Dunbar ME, Lanske B, Kronenberg H, Karaplis A, Broadus AE. Rescue of the parathyroid hormone-related protein knockout mouse demonstrates that parathyroid hormone-related protein is essential for mammary gland development. *Development*. 1998; 125:1285–1294. [PubMed: 9477327]
54. Yan R, Mo X, Paredes AM, Dai KS, Lanza F, Cruz MA, Li RH. Reconstitution of the platelet glycoprotein Ib-IX complex in phospholipid bilayer nanodiscs. *Biochemistry*. 2011; 50:10598–10606. [PubMed: 22080766]
55. Yao X, Parnot C, Deupi X, Ratnala VR, Swaminath G, Farrens D, Kobilka B. Coupling ligand structure to specific conformational switches in the beta2-adrenoceptor. *Nat Chem Biol*. 2006; 2:417–422. [PubMed: 16799554]

Figure 1. Schematic of purification of a family B GPCR in nanodiscs

The purification procedure includes (1) expression of a family B GPCR in a mammalian expression system, (2) solubilization of membrane components of the expression system using detergent, (3) incubation of solubilized membrane components with phospholipid and the membrane scaffold protein, MSP1E3D1 (4) addition of Bio-Beads to remove detergent by physical adsorption to induce formation of nanodiscs containing membrane proteins, (5) immuno-affinity binding of the GPCR incorporated in nanodiscs (GPCR-ND) to antibody-conjugated resin, (6) washing resins bound with GPCR-ND, and (7) elution with epitope to yield purified GPCR-ND.

Figure 2. Characterizations of physical properties of PTH1R-ND

(A) Size exclusion chromatogram of purified PTH1R-ND. (B) Transmission electron micrograph of negatively stained purified PTH1R-ND. Lower panel: images of PTH1R-ND with a scaling bar of 15 nm. (C) Coomassie-stained SDS-PAGE of the purified nanodisc preparation showing two major bands corresponding to MSP1E3D1 (~ 28 kD) and PTH1R (~ 75 kD).

Figure 3. Ligand-binding activity assay using fluorescence anisotropy

(A) PTH(1-34)-FAM peptide: (*Upper*) sequence of PTH(1-34) conjugated to 5(6)-carboxyfluorescein (FAM) at Lys13 and (*Lower*) structure of FAM. (B) Titration of PTH(1-34)-FAM (50 nM) with four nanodisc samples: (■) PTH1R-ND with 15 mM Ca^{2+} , (●) PTH1R-ND without added Ca^{2+} , (▲) PTH1R-ND with 200 μM EGTA, and (○) nanodiscs containing no PTH1R (empty-ND) with 15 mM Ca^{2+} . Indicated Ca^{2+} and EGTA concentrations are final. Buffer A: 20 mM Tris (pH 7.4), 150 mM NaCl, 100 μM EDTA and 3 mM MgCl_2 .

Figure 4. G-protein activity assay using BODIPY FL GTP γ S

(A) Structure of non-hydrolyzable and fluorescently labeled BODIPY FL GTP γ S. (B) Time-dependent BODIPY FL GTP γ S fluorescence signal monitored simultaneously in 4 sample slots in a fluorimeter. At $t = 0$, each sample slot contains a mixture of PTH1R-ND (20 nM), G_s (100 nM) and BODIPY FL GTP γ S (100 nM) in Buffer A; at $t \sim 6$ min, one of the following four solutions are added to each sample slot: (—) buffer, (—) 2 μ M PTH(1-34), (—) 2 μ M PTH(1-34) with 5 mM Ca²⁺, and (—) 2 μ M PTH(1-34) with 15 mM Ca²⁺. (C) Basal level or buffer subtracted time-dependent fluorescence signals. Buffer A: 20 mM Tris (pH 7.4), 150 mM NaCl, 100 μ M EDTA and 3 mM MgCl₂.

Figure 5. Control experiment: G-protein activity in the absence of PTH1R

At $t = 0$, two sample slots of the fluorimeter contain the reaction mixture of G_s (100 nM) and BODIPY FL GTP γ S (100 nM) in Buffer A. At $t \sim 45$ min, 15 mM Ca^{2+} is added to cuvette 1 (—), while buffer A is added to cuvette 2 (—). At $t \sim 90$ min, 20 nM (final concentration) of empty-ND is added to cuvette 1 (—), while plain buffer is added to cuvette 2 (—). The fluorescence remains unchanged except decreases due to dilution.

Figure 6. Calcium-dependent G-protein activity

Time-dependent BODIPY FL GTP γ S fluorescence signal monitored simultaneously in 2 or 3 sample slots in a fluorimeter. At $t = 0$, each sample slot contains PTH1R-ND (20 nM), G_s (100 nM) and BODIPY FL GTP γ S (100 nM) in Buffer A. (A) At $t \sim 15$ min, one of the following three solutions are added to each sample slot: (—) 2 μ M PTH(1-34), (—) 2 μ M PTH(1-34) with 200 μ M EGTA and (—) 2 μ M PTH(1-34) with 15 mM Ca^{2+} (B) At $t \sim 6$ min, two solutions are added to 2 sample slots: (—) buffer and (—) buffer with 200 μ M EGTA. (C) At $t = 8$ min, one of the three solutions are added to each of the three sample slots: (—) buffer, (—) 5 mM Ca^{2+} and (—) 2 μ M PTH(1-34) with 5 mM Ca^{2+} (specified as final concentrations).